Peptide topic · 7 records
Metabolic peptide medicines
These peptides do not all have the same proof. Check the exact product, people, result, and time period.
Before you compare
Start with four simple questions.
Use them as you open a peptide record or compare results.
- 01
What is the main result this topic can support?
- 02
Did the evidence come from people, animals, or cells?
- 03
Was the exact product and use tested?
- 04
What is still unknown about safety, quality, or personal use?
Exact limit
A weight or glucose result applies only to the studied molecule, product, people, outcome, and time period. It does not prove that every product sold under the same ingredient name works.
- Peptides reviewed
- 7
- Strongest evidence
- 4
- Claims checked
- 25
Research detailsRead the topic background and related guides
Topic summary
Compare approved products, peptides that researchers are still studying, and peptide fragments sold in the wellness market. They are not one category.
What these peptides have in common
The seven peptides reviewed here do not share one evidence stage. Semaglutide, tirzepatide, liraglutide, and insulin have FDA-approved products for defined uses. Retatrutide and cagrilintide are investigational and have human outcome research, but neither has an approved product. AOD-9604 was studied in human obesity programs, but the reviewed record does not establish meaningful weight loss.
What they have in common is a mechanism family, not a result. Each brief below records the studied population, endpoint, comparator, and duration separately from the marketing claim, because an approved indication belongs to one product for one use, and an investigational result belongs to the trial that produced it.
Research questions
Questions behind this topic.
- 01
Is there an approved product, an investigational program, or neither?
- 02
Was the endpoint weight, glucose, cardiovascular events, or only a biomarker?
- 03
Does the claim preserve the studied population and product?
Peptide records
Open each record to see its evidence.
- Approved human outcomesApproved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result.EstablishedAn official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone.
Semaglutide
This review covers Ozempic, Rybelsus, Wegovy, and the Wegovy HD strength. Their forms, approved uses, and labels differ.
3 claims checked · Open evidence brief ↗ - Approved human outcomesApproved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result.EstablishedAn official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone.
Insulin
Insulin is a family of diabetes medicines. Different products can have different timing, risks, and instructions.
3 claims checked · Open evidence brief ↗ - Approved human outcomesApproved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result.EstablishedAn official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone.
Tirzepatide
Some FDA-approved tirzepatide products have evidence for blood-sugar, weight, sleep-apnea, or heart-risk outcomes in specific groups of people. Each product's current label sets its uses and safety information.
3 claims checked · Open evidence brief ↗ - Approved human outcomesApproved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result.EstablishedAn official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone.
Liraglutide
An established prescription medicine. Its evidence applies to specific products, uses, groups of people, and current labels.
3 claims checked · Open evidence brief ↗ - Investigational human outcomesStudies measured health results in people, but the molecule is still being studied and is not approved for that use. Important questions remain.EmergingSome studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation.
Retatrutide
Still being studied. Late-stage study reports show meaningful results in people, but no product is approved and no regulatory review is complete.
6 claims checked · Open evidence brief ↗ - Investigational human outcomesStudies measured health results in people, but the molecule is still being studied and is not approved for that use. Important questions remain.EmergingSome studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation.
Cagrilintide
An investigational peptide made to act like the body's amylin signal. Human weight-loss studies exist, but no FDA-approved product exists.
4 claims checked · Open evidence brief ↗ - Investigational human outcomesStudies measured health results in people, but the molecule is still being studied and is not approved for that use. Important questions remain.InsufficientReliable studies in people are missing, too limited, or do not support the claim. This does not prove that the substance has no effect on the body.
AOD-9604
A modified piece of growth hormone studied in obesity programs. It has no approved use and unresolved route, product, and safety questions.
3 claims checked · Open evidence brief ↗